Code Biotherapeutics launches to develop nonviral-based gene therapies

By The Science Advisory Board staff writers

April 20, 2021 -- Code Biotherapeutics has launched with $10 million in financing and will focus on next-generation nonviral gene therapies.

The Philadelphia-based company has developed a proprietary synthetic DNA-based vector called 3DNA that has the potential to deliver genes of all sizes to multiple cell types as a redosable therapy for the treatment of many genetic disorders. Code is developing a pipeline of novel gene therapies to treat rare genetic diseases such as Duchenne muscular dystrophy and type 1 diabetes. The company is also actively seeking partnerships in other strategic areas.

The seed financing was co-led by 4BIO Capital and UPMC Enterprises, with participation from CureDuchenne Ventures, JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?